Clinical trials: High-Risk Prostate Cancer, open to volunteers
Prostatic Neoplasms
Dose Escalation For INtraprostatic LEsions
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer.
- Trial name
- DEFINE (NCT05851547)
- Testing
- Prostate SBRT with Focal Boost, Triptorelin Injection
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Prostate Cancer, Radiotherapy Side Effect
Prostate Reirradiation Toxicity Outcomes Feasibility Study
The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on…
- Trial name
- RO-PIP (NCT05614700)
- Testing
- Brachytherapy, Sterotactic Body Radiotherapy
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Prostate Cancer, Prostate Adenoma
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
The goal of this clinical trial is to evaluate efficacy and safety of radical prostatectomy (RP) with or without salvage radiotherapy versus RP with extended pelvic lymph node dissection (ePLND) in males who have localized…
- Trial name
- PRESEL (NCT07115992)
- Testing
- RARP±SRT, RARP+ePLND
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Ruijin Hospital
High-risk Prostate Cancer
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical…
- Trial name
- NCT06888102
- Testing
- Neoadjuvant Epigenetic Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Edwin Posadas, MD
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Adenocarcinoma
PSMA PET Response Guided SabR in High Risk Pca
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of…
- Trial name
- NCT06044857
- Testing
- 68-Ga PSMA11
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal…
- Trial name
- NCT07311915
- Testing
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Prostate Cancer
Implementation of Precision Medicine in High-risk Prostate Cancer
This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients.
- Trial name
- SPRINTR-REAL (NCT06687421)
- Testing
- High-risk treatment SOC, Active monitoring, Radical prostatectomy
- Where
- Sweden
- Volunteers
- 5,500 people
- Sponsor
- Andreas Josefsson
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Prostate Cancer
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with…
- Trial name
- NCT06220435
- Testing
- Ultra-hypofractionated radiotherapy regimen.
- Where
- 2 sites in Sweden
- Volunteers
- 76 people
- Sponsor
- Region Skane
Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
Bipolar Androgen Therapy + Carboplatin in mCRPC
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- HiTeCH (NCT03522064)
- Testing
- Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Cancer
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.
- Trial name
- PSMA SBRT-SIB (NCT04402151)
- Testing
- PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
- Trial name
- ProAMFocal (NCT06491056)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Patients With Prostate Cancer
High-Dose-Rate Brachytherapy
This pilot study initiates a research program testing the early technical and clinical performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy. Testing will proceed in two cohorts of patients.
- Trial name
- NCT00913939
- Testing
- MRI Guided Needles to deliver HDR Brachytherapy
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI).
- Trial name
- HypoElect (NCT06582446)
- Testing
- Androgen Deprivation Therapy (ADT) - Goserelin, High-Dose-Rate Interstitial Brachytherapy (HDR BRT), radiotherapy
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer Patients Treated by Radiotherapy
Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI
The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of…
- Trial name
- SIB-VMAT (NCT07693075)
- Testing
- Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT)
- Where
- 3 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Prostate Cancer
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan.
- Trial name
- VORTEX (NCT07293585)
- Testing
- Neurovascular sparing stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.